Related Experiment Video
Updated: Jun 5, 2026

New Application of an Atmospheric Pressure Plasma Jet as a Neuro-protective Agent Against Glucose Deprivation-induced Injury of SH-SY5Y Cells
Published on: October 9, 2017
Neuroprotective properties of GLP-1: theoretical and practical applications
Jens Juul Holst1, Remy Burcelin, Esther Nathanson
1Department of Biomedical Sciences, The Panum Institute, University of Copenhagen, Copenhagen, Denmark. jjholst@sund.ku.dk
Glucagon-like peptide-1 (GLP-1) enhances type 2 diabetes treatments and shows potential neuroprotective effects. Research explores GLP-1
Area of Science:
- Neuroscience
- Endocrinology
- Pharmacology
Background:
- Glucagon-like peptide-1 (GLP-1) based therapies (agonists and DPP-4 inhibitors) are established for type 2 diabetes.
- GLP-1 exerts extra-pancreatic effects, including central nervous system regulation of appetite and peripheral autonomic functions.
- Emerging evidence suggests a potential neuroprotective role for GLP-1.
Purpose of the Study:
- To summarize the evidence for GLP-1's neuronal activity.
- To examine the therapeutic potential of GLP-1 in neurological and neurodegenerative diseases.
Main Methods:
- Review of existing scientific literature on GLP-1's neurological effects.
- Analysis of data on GLP-1's role in Alzheimer's disease, Parkinson's disease, Huntington's disease, stroke, and neuropathy.
Main Results:
- GLP-1 demonstrates significant activity within the brain.
- Shared pathways of cell death may link type 2 diabetes with neurodegenerative disorders.
Conclusions:
- GLP-1 presents a promising therapeutic avenue for neurological conditions.
- Further research is warranted to fully elucidate GLP-1's neuroprotective capabilities and clinical applications.
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: Glinides
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are typically...
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Glial Cells